Cargando…

Impact of body mass index on real-world outcomes of rivaroxaban treatment in Japanese patients with non-valvular atrial fibrillation

This sub-analysis of the XAPASS, a prospective, single-arm, observational study, aimed to evaluate relationships between body mass index (BMI) and safety (major bleeding and all-cause mortality) and effectiveness [stroke/non-central nervous system (non-CNS) systemic embolism (SE)/myocardial infarcti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Murakawa, Yuji, Ikeda, Takanori, Ogawa, Satoshi, Kitazono, Takanari, Nakagawara, Jyoji, Minematsu, Kazuo, Miyamoto, Susumu, Hayashi, Yasuhiro, Kidani, Yoko, Okayama, Yutaka, Sunaya, Toshiyuki, Sato, Shoichiro, Yamanaka, Satoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Japan 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7332477/ https://www.ncbi.nlm.nih.gov/pubmed/32253531 http://dx.doi.org/10.1007/s00380-020-01587-z

Ejemplares similares

Outcomes associated with under-dosing of rivaroxaban for management of non-valvular atrial fibrillation in real-world Japanese clinical settings
por: Ikeda, Takanori, et al.
Publicado: (2019)

Real-world outcomes of rivaroxaban treatment in elderly Japanese patients with nonvalvular atrial fibrillation
por: Kitazono, Takanari, et al.
Publicado: (2019)

Real-world safety and effectiveness of rivaroxaban using Japan-specific dosage during long-term follow-up in patients with atrial fibrillation: XAPASS
por: Ikeda, Takanori, et al.
Publicado: (2021)

Impact of three major risk factors on clinical outcomes in patients with nonvalvular atrial fibrillation receiving rivaroxaban: Sub‐analysis from the XAPASS study
por: Ikeda, Takanori, et al.
Publicado: (2022)

Design and baseline characteristics of the Xarelto Post‐Authorization Safety & Effectiveness Study in Japanese Patients with Atrial Fibrillation (XAPASS)
por: Ogawa, Satoshi, et al.
Publicado: (2018)

Primary and secondary prevention of stroke and systemic embolism with rivaroxaban in patients with non-valvular atrial fibrillation: Sub-analysis of the EXPAND Study
por: Uchiyama, Shinichiro, et al.
Publicado: (2018)

Ischemic stroke, hemorrhage, and mortality in patients with non-valvular atrial fibrillation and renal dysfunction treated with rivaroxaban: sub-analysis of the EXPAND study
por: Atarashi, Hirotsugu, et al.
Publicado: (2021)

Clinical risk factors of stroke and major bleeding in patients with non-valvular atrial fibrillation under rivaroxaban: the EXPAND Study sub-analysis
por: Sakuma, Ichiro, et al.
Publicado: (2019)

Design and Baseline Data for a Prospective Observational Study of Rivaroxaban in Patients with Venous Thromboembolism in Japan (XASSENT)
por: Fukuda, Ikuo, et al.
Publicado: (2021)

Correction to: Clinical risk factors of stroke and major bleeding in patients with non-valvular atrial fibrillation under rivaroxaban: the EXPAND Study sub-analysis
por: Sakuma, Ichiro, et al.
Publicado: (2019)

Anticoagulation Intensity of Rivaroxaban for Stroke Patients at a Special Low Dosage in Japan
por: Okata, Takuya, et al.
Publicado: (2014)

Influence of cytochrome P450 polymorphisms on the antiplatelet effects of prasugrel in patients with non-cardioembolic stroke previously treated with clopidogrel
por: Kitazono, Takanari, et al.
Publicado: (2018)

RETRACTED ARTICLE: Effectiveness and safety of sorafenib for renal cell, hepatocellular and thyroid carcinoma: pooled analysis in patients with renal impairment
por: Oya, Mototsugu, et al.
Publicado: (2022)

Clinical implication of monitoring rivaroxaban and apixaban by using anti-factor Xa assay in patients with non-valvular atrial fibrillation
por: Ikeda, Kozue, et al.
Publicado: (2016)

Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban
por: Breithardt, Günter, et al.
Publicado: (2016)

Results of Prospective Cohort Study on Symptomatic Cerebrovascular Occlusive Disease Showing Mild Hemodynamic Compromise [Japanese Extracranial-Intracranial Bypass Trial (JET)-2 Study]
por: KATAOKA, Hiroharu, et al.
Publicado: ( 201)

THrombolysis for Acute Wake-up and unclear-onset Strokes with alteplase at 0·6 mg/kg (THAWS) Trial
por: Koga, Masatoshi, et al.
Publicado: (2014)

Safety and effectiveness of sorafenib in Japanese patients with hepatocellular carcinoma in daily medical practice: interim analysis of a prospective postmarketing all-patient surveillance study
por: Kaneko, Shuichi, et al.
Publicado: (2016)

Rivaroxaban administration after acute ischemic stroke: The RELAXED study
por: Yasaka, Masahiro, et al.
Publicado: (2019)

Bleeding and Thromboembolic Events in Patients with Non-Valvular Atrial Fibrillation Treated with Apixaban or Rivaroxaban
por: ABDULLAH, Ahmad Salihin, et al.
Publicado: (2022)

Efficacy and Safety of Prasugrel by Stroke Subtype: A Sub-Analysis of the PRASTRO-I Randomized Controlled Trial
por: Kitazono, Takanari, et al.
Publicado: (2021)

Comparative effectiveness of dabigatran, rivaroxaban, apixaban and warfarin in the management of patients with non-valvular atrial fibrillation
por: Pink, Joshua, et al.
Publicado: (2013)

Bleeding risk with dabigatran, rivaroxaban, warfarin, and antiplatelet agent in Asians with non-valvular atrial fibrillation
por: Chan, Yi-Hsin, et al.
Publicado: (2017)

Effectiveness and safety of rivaroxaban vs. warfarin in patients with non‐valvular atrial fibrillation and heart failure
por: Martinez, Brandon K., et al.
Publicado: (2018)

Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation
por: Norby, Faye L., et al.
Publicado: (2017)

DOACs in Valvular Heart Disease: Latest Key Updates on PROACT Xa (Apixaban) and INVICTUS (Rivaroxaban)
por: Ryu, Rachel
Publicado: (2022)

Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation
por: Cappato, Riccardo, et al.
Publicado: (2015)

Real-world safety and effectiveness of radium-223 in Japanese patients with castration-resistant prostate cancer (CRPC) and bone metastasis: exploratory analysis, based on the results of post-marketing surveillance, according to prior chemotherapy status and in patients without concomitant use of second-generation androgen-receptor axis-targeted agents
por: Uemura, Hirotsugu, et al.
Publicado: (2021)

Japanese and Non-Japanese Patients with Transient Ischemic Attack or Minor Stroke: A Five-Year Risk Analysis of Stroke and Vascular Events
por: Uchiyama, Shinichiro, et al.
Publicado: (2021)

Rivaroxaban Underdose for Atrial Fibrillation with Stable Coronary Disease: The AFIRE Trial Findings
por: Arashi, Hiroyuki, et al.
Publicado: (2022)

Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: A nationwide pharmacoepidemiological study
por: Kjerpeseth, Lars J., et al.
Publicado: (2019)

Dabigatran, rivaroxaban, and apixaban are superior to warfarin in Asian patients with non-valvular atrial fibrillation: An updated meta-analysis
por: Li, Wei-Jia, et al.
Publicado: (2021)

Effect of Evidence-Based Pharmacy Care on Satisfaction and Cognition in Patients with Non-Valvular Atrial Fibrillation Taking Rivaroxaban
por: Sun, Jie, et al.
Publicado: (2021)

Increased Levels of Platelets and Endothelial-Derived Microparticles in Patients With Non-Valvular Atrial Fibrillation During Rivaroxaban Therapy
por: Lenart-Migdalska, Aleksandra, et al.
Publicado: (2021)

Population Pharmacokinetics and Dose Optimization Based on Renal Function of Rivaroxaban in Thai Patients with Non-Valvular Atrial Fibrillation
por: Singkham, Noppaket, et al.
Publicado: (2022)

Cost-effectiveness Analysis of Rivaroxaban versus Acenocoumarol in the Prevention of Stroke in Patients with Non-valvular Atrial Fibrillation in Spain
por: Rubio-Terrés, Carlos, et al.
Publicado: (2016)

Safety and effectiveness of riociguat for chronic thromboembolic pulmonary hypertension in real-world clinical practice: interim data from post-marketing surveillance in Japan
por: Tanabe, Nobuhiro, et al.
Publicado: (2020)

A large-scale prospective registration study of the safety and efficacy of sorafenib tosylate in unresectable or metastatic renal cell carcinoma in Japan: results of over 3200 consecutive cases in post-marketing all-patient surveillance
por: Akaza, Hideyuki, et al.
Publicado: (2015)

Early initiation of rivaroxaban after reperfusion therapy for stroke patients with nonvalvular atrial fibrillation
por: Koge, Junpei, et al.
Publicado: (2022)

Non-Traumatic Spontaneous Spinal Subdural Hematoma in a Patient with Non-Valvular Atrial Fibrillation During Treatment with Rivaroxaban
por: Castillo, Jessica M., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_8710b2qdg77oqd621rker4ju9j